On the anticipation of the human dose in first-in-man trials from preclinical and prior clinical information in early drug development

Author： Lowe P. J.   Hijazi Y.   Luttringer O.   Yin H.   Sarangapani R.   Howard D.  

Publisher： Informa Healthcare

ISSN： 1366-5928

Source： Xenobiotica, Vol.37, Iss.10-11, 2007-11, pp. : 1331-1354

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Novel Agents Targeting Crucial Signalling Pathways in Head and Neck Squamous Cell Carcinoma, HNSCC - Preclinical Development and Data from Clinical Trials

By  

Current Proteomics, Vol. 10, Iss. 2, 2013-07 ,pp. : 150-164

Bentham Science Publishers

Access to resources Recommend Favorite

Implications and consequences of enzyme induction on preclinical and clinical drug development

By Worboys P. D.   Carlile D. J.  

Xenobiotica, Vol. 31, Iss. 8-9, 2001-08 ,pp. : 539-556

Informa Healthcare

Access to resources Recommend Favorite

Berberine on metabolic and cardiovascular risk factors: an analysis from preclinical evidences to clinical trials

By Derosa Giuseppe   Maffioli Pamela   Cicero Arrigo FG  

Expert Opinion on Biological Therapy, Vol. 12, Iss. 8, 2012-08 ,pp. : 1113-1124

Informa Healthcare

Access to resources Recommend Favorite

Development of a cytomegalovirus vaccine: lessons from recent clinical trials

By Gonczol E.   Plotkin S.  

Expert Opinion on Biological Therapy, Vol. 1, Iss. 3, 2001-05 ,pp. : 401-412

Informa Healthcare

Access to resources Recommend Favorite

Necitumumab in the treatment of advanced non-small cell lung cancer: translation from preclinical to clinical development

By Dienstmann Rodrigo   Felip Enriqueta  

Expert Opinion on Biological Therapy, Vol. 11, Iss. 9, 2011-09 ,pp. : 1223-1231

Informa Healthcare

Access to resources Recommend Favorite